Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A. Li T, et al. Among authors: maitland ml. J Hematol Oncol. 2016 Mar 10;9:23. doi: 10.1186/s13045-016-0254-5. J Hematol Oncol. 2016. PMID: 26966027 Free PMC article. Clinical Trial.
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E. Maitland ML, et al. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083232 Free PMC article.
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Sharma MR, et al. Among authors: maitland ml. Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553850 Free PMC article. Clinical Trial.
Cardiovascular toxicity of new agents.
Maitland ML. Maitland ML. Clin Adv Hematol Oncol. 2008 Sep;6(9):657-9. Clin Adv Hematol Oncol. 2008. PMID: 18827788 No abstract available.
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Karovic S, et al. Among authors: maitland ml. Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17. Clin Pharmacol Ther. 2014. PMID: 24637941 Free PMC article. Clinical Trial.
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Maitland ML, et al. Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19. Br J Cancer. 2018. PMID: 29551775 Free PMC article. Clinical Trial.
Advances in biomarkers for targeted agents.
Maitland ML. Maitland ML. Clin Adv Hematol Oncol. 2011 Sep;9(9):688-90. Clin Adv Hematol Oncol. 2011. PMID: 22402514 No abstract available.
87 results